## JC10 Rec'd PCT/PTO 3:0 MAR 2005

FILING BY "EXPRI	ESS MAIL" UNDER 37 CFR 1.10
EV 524615104 US	30 March 2005
Express Mail Label Number	Date of Deposit

Form PTO-1390-MOD (REV 10-96)			Department of Commerce Patent and Trademark Office	ATTORNEY'S DOCKET NUMBER 4-32702A						
TRANSMITTAL LETTER TO TI			HE LINITED STATES	S. APPLICATION NO. (If known, see 37_CFR 1.5)						
		DESIGNATED/ELECTED O	10/529613							
		CONCERNING A FILING UN	10/20/0-2							
INT	ERI	NATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED						
	PCT/EP03/10798 29 September 2003 (29.09.03) 30 September 2002 (30.09.02)									
	TITLE OF INVENTION METHODS TO TREAT CHOLESTEROL ELEVATIONS DURING IMMUNOSUPPRESSANT THERAPY									
APPLICANT(S) FOR DO/EO/US										
KUDARAVALLI ET AL.										
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:										
1. 2. 3.		This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.  This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.  This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).  A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority								
_		date.								
5.	IXI	<ul> <li>A copy of the International Application as filed (35 U.S.C. 371(c)(2))</li> <li>a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).</li> <li>b. ☐ has been transmitted by the International Bureau. (See Form PCT/IB/308)</li> <li>c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).</li> <li>A translation of the International Application into English (35 U.S.C. 371(c)(2)).</li> </ul>								
6.										
7.	<ul> <li>Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C.371(c)(3)).</li> <li>a. are transmitted herewith (required only if not transmitted by the International Bureau).</li> <li>b. have been transmitted by the International Bureau.</li> </ul>									
		<ul> <li>c.  have not been made; however, the</li> <li>d.  have not been made and will not</li> </ul>	ne time limit for making such amendmer be made.	its rias NO1 expired.						
8. 9. 10.		A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).  An executed Declaration and Power of Attorney (original or copy) (35 U.S.C. 371(c)(4)).								
Items 11. to 16. below concern document(s) or information included.										
11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.										
12.		An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.								
13.		A FIRST preliminary amendment.  A SECOND or SUBSEQUENT preliminary amendment.								
14.	$\boxtimes$	An Application Data Sheet under 37 CFR 1.76.								
15.		A substitute specification.								
16.		A change of power of attorney and/or address letter.								
17.	$\boxtimes$	A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825.								
18.		A second copy of the published Internation								
19.		A second copy of the English language tr	anslation of the International application	n under 35 U.S.C. 154(d)(4).						
20.	$\boxtimes$	☑ Other items or information: An unexecuted Declaration								

U.S. APPLICATI	ON NO. NUMBER	/ 5 °	20 <u>6</u>	13	
The followi	ng fees ar	e subm	itted:		

U.S. AFFBOATION 1	(Commerce of	<b>J</b>	PC1	r/EP03/10798				4-32702A			
The following fee	es are su	ıbmitted:								CULATIO	NS PTO USE
							ONLY				
21. 🛭 Basid	⊠ Basic national fee										
22. Examinatio	n Fee										
☐ If Inte								\$			
. All other situations							\$200				
23. Search fee  If Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority. \$  If International Search Report was prepared and provided to the Office. \$400  All other situations. \$											
				21, 22 AND 23					\$	900	
Additional fee fo program listing f thereof.	r specific iled in ar	cation and on electronic	rawings filed in medium). The	n paper over 10 e fee is <b>\$250</b> for	0 sheets (e each additi	xcludii ional 5	ng sequ 0 shee	uence listing of ts of paper or	or con fracti	nputer on	
Total Sheets	Extra	sheets		nch additional 50 d <b>up</b> to a whole				ATE			
40 - 100 =	0	/50 =		0		X	\$	250	\$		
Surcharge of \$1 months from the					□ 30				\$		
CLAIMS		NUMB	ER FILED	NUMBER E	XTRA		RA				
Total claims	•	19	- 20 =	5		X	<u>\$</u> \$	50 200	\$ \$	1,000	
Independent cla MULTIPLE DEP		E CLAIM(S				<u>X</u>	<u> </u>	360	\$	1,000	
MOETH EE DEI	LINDLIN	T OB AIM (O	(п аррпоавіс)	TOTAL OF	ABOVE	CAL			\$	1,900	
Reduction of 1/2	for filing	by small e	ntity, if applica							<u> </u>	·
filed (Note 37 CI	FR 1.9, 1	1.27, 1.28).			<u> </u>		OLID	TOTAL -	\$ \$	4 000	
Processing fee	£ #420 £	ar furnishin	a the English t	ranalation later t	bon 12	0 mon		TOTAL =	<b>P</b>	1,900	
earliest claimed				iansialion later i	ulali 🔲 5	o mon	113 1101	+	\$		
		•			TOTA	L NA	TION	AL FEE =	\$	1,900	
Fee for recording	g the en	closed assi	gnment (37 CF	R 1.21(h)). The	e assignme	nt mus	t be ac	companied		•	
by an appropriat	e cover	sheet (37 C	FR 3.28, 3.31	). <b>\$40</b> per prope		EEE	ENC	LOSED =	\$	1,900	
					TOTAL	EES	ENC	LOSED =			
										mount to refunded	\$
										charged	\$
a. A chec	k in the a	amount of \$		to cover the	above fees	s is en	closed.				
c.   The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0134 in the name of Novartis.											
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status											
Send all correspondence to the address associated with Customer No. 001095, which is currently:											
Novartis Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080 Dated: March 30, 2005						ants			_		